A healthcare employee injects a person with the Moderna COVID-19 vaccine at the Dennis Avenue Health Center in Silver Spring, Maryland on November 21, 2022. While COVID-19 remains a serious concern for this holiday season, rose in early trading on Monday, just days after the pharma company submitted an application to the Food and Drug Administration (FDA) for the authorization of an updated vaccine.The stock's current valuation reflects uncertainty around Covid vaccine revenues, according t Eliana Merle upgraded the rating for Moderna from Neutral to Buy, while reducing the price target from $221 to $191. PHOTO BY ERIC LEE/GETTY IMAGES
Shares of Moderna Inc (NASDAQ: MRNA) rose in early trading on Monday, just days after the pharma company submitted an application to the Food and Drug Administration (FDA) for the authorization of an updated vaccine.
The stock’s current valuation reflects uncertainty around Covid vaccine revenues, according t Eliana Merle upgraded the rating for Moderna from Neutral to Buy, while reducing the price target from $221 to $191.
Sign up to read this article
Read news from 100's of titles, curated specifically for you.
